Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bristol Myers Squibb Gets Subpoena for Abilify Information

Feb. 17 (Bloomberg) -- Bristol-Myers Squibb Co. said it received a subpoena from the U.S. attorney’s office in New York asking for information about sales and marketing of its second-best-selling drug, Abilify, used to treat schizophrenia and other mood disorders.

“It’s not possible at this time to assess the outcome of this matter or its potential impact on the company,” the New York-based firm said in a filing today with the U.S. Securities and Exchange Commission. The subpoena was received last month.

The Abilify antipsychotic drug generated $2.8 billion in revenue in 2011, second after the blood thinner Plavix in the company’s portfolio, according to data compiled by Bloomberg. Abilify faces generic competition in 2013 and 2015 and Plavix loses patent protection this year, the company has said.

Shares of Bistol-Myers Squibb rose 62 cents or 1.9 percent to $32.66 in New York Stock Exchange composite trading at 10:13 a.m.

Laura Hortas, a company spokeswoman, declined to comment on the subpoena beyond the company’s statement.

To contact the reporters on this story: Phil Milford in Wilmington, Delaware, at pmilford@bloomberg.net; Sarah Frier in New York at sfrier1@bloomberg.net.

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.